Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Cancer Res. 2011 Apr 15;71(13):4585–4597. doi: 10.1158/0008-5472.CAN-11-0127

Figure 1.

Figure 1

The combination of trastuzumab and glycolysis inhibitors synergistically inhibits cancer cell growth.

A, BT474, B, ZR-7530 and C, SKBR3 cells were seeded in 96-well plates at 5 × 103 cells/well. After 24 hrs, cells were treated with the indicated concentration of trastuzumab (Ttzm), 2-deoxyglucose (2-DG), oxamate (OX), or Ttzm plus 2-DG (left)/OX (right) and incubated for 48 hrs, and cell viability was determined. Data are presented as the percentage of viability inhibition measured in cells not treated with Ttzm and 2-DG/OX. Columns, mean of three independent experiments; bars, SE. S, synergy (CI< 1.0).